Barclays raised the firm’s price target on Waters to $330 from $300 and keeps an Underweight rating on the shares. Investor sentiment towards the life science tools and diagnostics group has improved since the nadir of Q2 as the end markets are in a better place to start Q3 than they were last quarter, the analyst tells investors in a research note. Heading into the Q3 report, Barclays likes names with “idiosyncratic growth drivers” that will lead to core growth at the high end or above the rest of peers. It also likes stocks with multiples trading within historical ranges that can give valuation support for more upside and a potential breakout of the trading range.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WAT:
- Microsoft, Qualcomm downgraded: Wall Street’s top analyst calls
- Waters upgraded to Buy from Hold at Jefferies
- Waters price target raised to $355 from $335 at Evercore ISI
- Foot Locker trips after earnings, Kohl’s posts Q2 beat: Morning Buzz
- Illumina upgraded, Fiserv initiated: Wall Street’s top analyst calls